Navigation Links
Stereotaxis Announces First Uses of the NAVISTAR(R) RMT THERMOCOOL(R) Catheter
Date:3/6/2009

ST. LOUIS, March 6 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) announced today that clinicians at two centers in the United States have performed successful cardiac ablation procedures with the NAVISTAR(R) RMT THERMOCOOL(R) catheter since the announcement of its approval by the U.S. Food and Drug Administration on February 26.

In the first procedure with the magnetic irrigated catheter, Dr. Andrea Natale, Executive Medical Director of the Texas Cardiac Arrhythmia Institute at St. David's Medical Center in Austin, Texas, successfully treated a 65-year old male with persistent left-sided abnormal heart rhythm.

"This was a very complicated case," said Dr. Natale. "The procedure was flawless, and the patient is doing extremely well. We are very pleased with the performance of the magnetic irrigated catheter. Now that it is available, we expect to use the Remote Magnetic Navigation System routinely to treat complex arrhythmias. The power of the magnetic irrigated catheter together with the precision of the Stereotaxis System represents a significant improvement in the management of complex arrhythmias."

In a separate case, Dr. David Tschopp, electrophysiologist at The Heart Hospital of Austin, treated a 72-year old male patient with atrial flutter.

"The performance of the magnetic irrigated catheter was exceptional," said Dr. Tschopp. "We were able to deliver the necessary therapy and the patient is doing extremely well. I believe that the combination of remote magnetic navigation with the irrigated catheter will have the greatest, most immediate impact on treating complex left sided ablations. It is exciting for this tool to be available to the millions of people who have this disease."

Prior to FDA approval, Dr. Peter Weiss, MD MSc at Intermountain Medical Center in Salt Lake City, received a compassionate use exemption to treat a patient suffering from incessant premature ventricular contractions (PVCs) that accounted for over 30% of his heart beats each day. After treatment with the magnetic irrigated catheter, the patient's PVCs were reduced to less than 5% of his total heart beats. The patient had failed medications and two previous attempts at catheter ablation.

"The details of our case at Intermountain demonstrate the full power of an irrigated catheter combined with the precision of magnetic navigation," said Dr. Weiss. "We were able to maneuver the catheter into very difficult-to-reach anatomy, achieve excellent tissue-catheter contact, and successfully treat this complicated patient where other treatments had failed. This has been an extremely gratifying case and we look forward to broader and more consistent application of the magnetic irrigated catheter for complex cases at our Center going forward."

"Everyone at Stereotaxis has been preparing for the introduction of the magnetic irrigated catheter in the U.S.," said Mike Kaminski, Stereotaxis President and CEO. "With these first cases we have begun with our partner a phased rollout to our installed base of Niobe systems and we are working very diligently to be certain each center has the training and resources it needs to deploy the catheter with success. We're looking forward to seeing a broader presentation of clinical experiences at the Heart Rhythm Society's annual meeting in May."

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis System have received regulatory clearance in the U.S., Europe, and Canada and elsewhere.

About Forward-Looking Statements

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that we will recognize revenue related to our purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of our control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.


'/>"/>
SOURCE Stereotaxis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Stereotaxis Announces FDA Approval of the NAVISTAR(R) RMT THERMOCOOL(R) Catheter
2. Stereotaxis Reports Fourth Quarter 2008 Financial Results
3. Stereotaxis Annouces First CTO Crossing Procedure With RF PowerAssert(TM) Magnetic Guidewire
4. Stereotaxis to Raise $20 Million in Registered Direct Offering of Common Stock and Warrants
5. Stereotaxis Reports Third Quarter 2008 Financial Results
6. Stereotaxis Announces New Management Appointment
7. Stereotaxis Reports Record Second Quarter Revenue
8. Stereotaxis Announces Second Quarter 2008 Earnings Release Date and Conference Call
9. Stereotaxis Magnetic Navigation System Used to Successfully Treat an Inoperable Congenital Heart Defect in a 10-Year Old Patient
10. Stereotaxis Reports Record First Quarter Orders
11. Stereotaxis to Present at the Deutsche Bank 33rd Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... ... past six years, Lightning Labels has sent out a call for users of its custom ... creativity of their designs. Submissions this year were open from May 18 to July 1 ... winners of the sixth annual Photo Contest, along with the prizes they've received:, ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Wilderness Voices”: a collection ... travel. “Wilderness Voices” is the creation of published author, Martha McKown, an ordained ... was inspired as a very young child when her older sisters studied High School ...
(Date:8/22/2017)... ... , ... TopConsumerReviews.com recently gave a best-in-class 5-star rating to Energy NADH, a ... of modern life continually makes more demands on time and energy, people are finding ... people in vicious high/low cycles and can also cause long term health issues. More ...
(Date:8/21/2017)... ... August 22, 2017 , ... ... I. Stevens as a 2017-2018 inductee into its VIP Woman of the ... NAPW is the nation’s leading networking organization exclusively for professional women, boasting more ...
(Date:8/21/2017)... ... 2017 , ... Marathon running has surged in popularity in ... running increases exposure to ultraviolet radiation, a carcinogen that promotes skin cancer. Studies ... half may be adequately protecting themselves with proper clothing and sunscreen. , ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... , Aug. 2, 2017 ... Who,s Who as a Pinnacle Lifetime Professional in ... Key Account Manager at Turing Pharmaceuticals, AG. Her ... troubleshooting and relationship building.                ... more than 25 years of experience as a ...
(Date:7/31/2017)... Pharmacy, Inc. (NYSE: DPLO), has been named one of the ... Crain,s Detroit Business . The annual Crain,s Fast ... growth. This year,s edition measures growth from 2013 to 2016. ... list, visit crainsdetroit.com/awards/fast_50/2017 .  "Being named ... Phil Hagerman , CEO and chairman of Diplomat. "We,ve made ...
(Date:7/27/2017)... 2017  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ... 30, 2017.  The Company reported second quarter net sales ... prior year period, and an increase of 2.1% on ... of contribution from the LDR Holding Corporation acquisition, second ... of 2016, or 0.3% on a constant currency basis. ...
Breaking Medicine Technology: